Haemonetics beats earnings by $0.05, revenue tops estimates

au.investing.com

Haemonetics beat earnings estimates by $0.05 per share, and its revenue also topped analyst forecasts for the quarter. The results reflect stronger-than-expected performance at the medical technology company, which focuses on blood management and plasma collection. Both key metrics surpassed Wall Street consensus in the latest reporting period. Haemonetics' quarterly update comes amid ongoing demand for blood and plasma products. Specific revenue totals and net income figures were not disclosed in the announcement.


With a significance score of 0.9, this news ranks in the top 76% of today's 29897 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Haemonetics beats earnings by $0.05, revenue tops estimates | News Minimalist